JP2018521691A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018521691A5 JP2018521691A5 JP2018522867A JP2018522867A JP2018521691A5 JP 2018521691 A5 JP2018521691 A5 JP 2018521691A5 JP 2018522867 A JP2018522867 A JP 2018522867A JP 2018522867 A JP2018522867 A JP 2018522867A JP 2018521691 A5 JP2018521691 A5 JP 2018521691A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- antibody
- chain polypeptide
- protein
- tfr antibody
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004169 proteins and genes Human genes 0.000 claims 18
- 108090000623 proteins and genes Proteins 0.000 claims 18
- 229920001184 polypeptide Polymers 0.000 claims 16
- 102000004196 processed proteins & peptides Human genes 0.000 claims 16
- 108090000765 processed proteins & peptides Proteins 0.000 claims 16
- 230000010056 antibody-dependent cellular cytotoxicity Effects 0.000 claims 3
- 238000010367 cloning Methods 0.000 claims 3
- 239000013599 cloning vector Substances 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 239000013604 expression vector Substances 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 2
- 102000007238 Transferrin Receptors Human genes 0.000 claims 2
- 108010033576 Transferrin Receptors Proteins 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 102000039446 nucleic acids Human genes 0.000 claims 2
- 108020004707 nucleic acids Proteins 0.000 claims 2
- 150000007523 nucleic acids Chemical class 0.000 claims 2
- 101710112752 Cytotoxin Proteins 0.000 claims 1
- 208000009329 Graft vs Host Disease Diseases 0.000 claims 1
- 206010025323 Lymphomas Diseases 0.000 claims 1
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 claims 1
- 239000004480 active ingredient Substances 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000036639 antigens Human genes 0.000 claims 1
- 108091007433 antigens Proteins 0.000 claims 1
- 230000006907 apoptotic process Effects 0.000 claims 1
- 239000000969 carrier Substances 0.000 claims 1
- 238000012258 culturing Methods 0.000 claims 1
- 231100000599 cytotoxic agent Toxicity 0.000 claims 1
- 239000002619 cytotoxin Substances 0.000 claims 1
- 230000003247 decreasing effect Effects 0.000 claims 1
- 229940039227 diagnostic agent Drugs 0.000 claims 1
- 239000000032 diagnostic agent Substances 0.000 claims 1
- 239000003085 diluting agent Substances 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 208000024908 graft versus host disease Diseases 0.000 claims 1
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 claims 1
- 208000027866 inflammatory disease Diseases 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 231100001258 radiotoxin Toxicity 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15306192.4 | 2015-07-22 | ||
| EP15306192 | 2015-07-22 | ||
| PCT/EP2016/067465 WO2017013230A1 (en) | 2015-07-22 | 2016-07-21 | ANTI-TfR ANTIBODIES AND THEIR USE IN TREATING PROLIFERATIVE AND INFLAMMATORY DISORDERS |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018521691A JP2018521691A (ja) | 2018-08-09 |
| JP2018521691A5 true JP2018521691A5 (cg-RX-API-DMAC7.html) | 2019-08-29 |
| JP6858185B2 JP6858185B2 (ja) | 2021-04-14 |
Family
ID=53776520
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2018522867A Active JP6858185B2 (ja) | 2015-07-22 | 2016-07-21 | 増殖性および炎症性疾患の処置における抗ＴｆＲ抗体およびその使用 |
Country Status (22)
Families Citing this family (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10179817B2 (en) | 2015-05-04 | 2019-01-15 | Cytomx Therapeutics, Inc. | Anti-CD71 antibodies, activatable anti-CD71 antibodies, and methods of use thereof |
| FR3062213B1 (fr) | 2017-01-20 | 2021-02-26 | Endodiag | Utilisation du recepteur cd71 dans la detection et le traitement de l’endometriose |
| EP3552631A1 (en) * | 2018-04-10 | 2019-10-16 | Inatherys | Antibody-drug conjugates and their uses for the treatment of cancer |
| EA202190416A1 (ru) | 2018-08-02 | 2021-06-23 | Дайн Терапьютикс, Инк. | Мышечно-специфические комлексы и их применение для лечения плече-лопаточно-лицевой мышечной дистрофии |
| US11168141B2 (en) | 2018-08-02 | 2021-11-09 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| WO2020028832A1 (en) | 2018-08-02 | 2020-02-06 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US12018087B2 (en) | 2018-08-02 | 2024-06-25 | Dyne Therapeutics, Inc. | Muscle-targeting complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and methods of delivering oligonucleotide to a subject |
| US11911484B2 (en) | 2018-08-02 | 2024-02-27 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12097263B2 (en) | 2018-08-02 | 2024-09-24 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| US12370264B1 (en) | 2018-08-02 | 2025-07-29 | Dyne Therapeutics, Inc. | Complexes comprising an anti-transferrin receptor antibody linked to an oligonucleotide and method of delivering oligonucleotide to a subject |
| US20220411527A1 (en) * | 2019-11-06 | 2022-12-29 | The Regents Of The University Of California | Compositions and methods for transferrin receptor 1 targeting |
| CN115427059A (zh) * | 2020-01-31 | 2022-12-02 | 达因疗法公司 | 抗转铁蛋白受体（tfr）抗体及其用途 |
| US11638761B2 (en) | 2021-07-09 | 2023-05-02 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating Facioscapulohumeral muscular dystrophy |
| US11969475B2 (en) | 2021-07-09 | 2024-04-30 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating facioscapulohumeral muscular dystrophy |
| JP2024525608A (ja) | 2021-07-09 | 2024-07-12 | ダイン セラピューティクス，インコーポレーテッド | ジストロフィン異常症を処置するための筋標的化複合体および製剤 |
| US11771776B2 (en) | 2021-07-09 | 2023-10-03 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating dystrophinopathies |
| US11672872B2 (en) | 2021-07-09 | 2023-06-13 | Dyne Therapeutics, Inc. | Anti-transferrin receptor antibody and uses thereof |
| US11633498B2 (en) | 2021-07-09 | 2023-04-25 | Dyne Therapeutics, Inc. | Muscle targeting complexes and uses thereof for treating myotonic dystrophy |
| CA3230796A1 (en) | 2021-09-01 | 2023-03-09 | Biogen Ma Inc. | Anti-transferrin receptor antibodies and uses thereof |
| TW202330601A (zh) * | 2021-09-13 | 2023-08-01 | 德州大學系統董事會 | ＴｆＲ抗原結合蛋白及其用途 |
| CN119183457A (zh) | 2022-04-15 | 2024-12-24 | 达因疗法公司 | 用于治疗强直性肌营养不良的肌肉靶向复合物和制剂 |
| KR20250114322A (ko) * | 2022-12-02 | 2025-07-29 | 바이오사이토젠 파마슈티컬스 (베이징) 컴퍼니 리미티드 | 항-tfr1 항체 및 이의 용도 |
| KR20250164751A (ko) | 2023-03-24 | 2025-11-25 | 데날리 테라퓨틱스 인크. | A베타 표적화 단백질 및 사용 방법 |
| EP4477236A1 (en) | 2023-06-14 | 2024-12-18 | Inatherys | Combination therapy for treating a tumor using adc comprising anti-cd71 antibodies and bh3 mimetics |
| TW202517685A (zh) * | 2023-10-26 | 2025-05-01 | 美商百健Ｍａ公司 | 抗運鐵蛋白受體抗體及其用途 |
| WO2025140522A1 (en) * | 2023-12-29 | 2025-07-03 | Nona Biosciences (Suzhou) Co., Ltd. | Anti-tfr1 antibodies, preparation methods and uses thereof |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4434156A (en) | 1981-10-26 | 1984-02-28 | The Salk Institute For Biological Studies | Monoclonal antibodies specific for the human transferrin receptor glycoprotein |
| PL209786B1 (pl) * | 1999-01-15 | 2011-10-31 | Genentech Inc | Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna |
| EP2353611B1 (en) | 2002-07-31 | 2015-05-13 | Seattle Genetics, Inc. | Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease |
| WO2005011082A2 (en) | 2003-07-23 | 2005-02-03 | Univeral Infusion Technology | Drive motor transmission system |
| ES2379526T3 (es) * | 2004-04-30 | 2012-04-27 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Anticuerpo anti-TfR |
| CA2569692C (en) * | 2004-06-07 | 2015-07-21 | Raven Biotechnologies, Inc. | Transferrin receptor antibodies |
| EP1896582A4 (en) * | 2005-05-09 | 2009-04-08 | Ono Pharmaceutical Co | HUMAN MONOCLONAL ANTIBODIES AGAINST PROGRAMMED CELL DEATH 1 (PD-1) AND METHOD FOR CREATING TREATMENT WITH ANTI-PD-1 ANTIBODIES ALONE OR IN COMBINATION WITH OTHER IMMUNOTHERAPEUTICS |
| FR2953841B1 (fr) | 2009-12-16 | 2011-12-30 | Centre Nat Rech Scient | Anticorps diriges contre le recepteur de la transferrine et leurs utilisations pour l'immunotherapie des tumeurs qui dependent du fer |
| US20150197574A1 (en) * | 2012-08-02 | 2015-07-16 | Inserm (Institut National De La Sante Et De La Recherche Medicale) | Use of transferrin receptor antagonist for the treatment of thalassemia |
| HRP20181453T1 (hr) * | 2012-11-08 | 2018-12-14 | University Of Miyazaki | Protutijelo koje može specifično prepoznavati receptor transferina |
| EP3552631A1 (en) * | 2018-04-10 | 2019-10-16 | Inatherys | Antibody-drug conjugates and their uses for the treatment of cancer |
-
2016
- 2016-07-21 IL IL257065A patent/IL257065B/en unknown
- 2016-07-21 LT LTEP16744353.0T patent/LT3325509T/lt unknown
- 2016-07-21 PL PL16744353T patent/PL3325509T3/pl unknown
- 2016-07-21 JP JP2018522867A patent/JP6858185B2/ja active Active
- 2016-07-21 RU RU2018106364A patent/RU2737637C2/ru active
- 2016-07-21 HU HUE16744353A patent/HUE053296T2/hu unknown
- 2016-07-21 SM SM20210134T patent/SMT202100134T1/it unknown
- 2016-07-21 MX MX2018000569A patent/MX2018000569A/es unknown
- 2016-07-21 KR KR1020187004745A patent/KR102690998B1/ko active Active
- 2016-07-21 CN CN201680040714.2A patent/CN107849136B/zh active Active
- 2016-07-21 PT PT167443530T patent/PT3325509T/pt unknown
- 2016-07-21 HR HRP20210393TT patent/HRP20210393T1/hr unknown
- 2016-07-21 SI SI201631117T patent/SI3325509T1/sl unknown
- 2016-07-21 CA CA2992509A patent/CA2992509C/en active Active
- 2016-07-21 RS RS20210280A patent/RS61586B1/sr unknown
- 2016-07-21 WO PCT/EP2016/067465 patent/WO2017013230A1/en not_active Ceased
- 2016-07-21 ES ES16744353T patent/ES2860988T3/es active Active
- 2016-07-21 DK DK16744353.0T patent/DK3325509T3/da active
- 2016-07-21 AU AU2016296321A patent/AU2016296321B2/en active Active
- 2016-07-21 EP EP16744353.0A patent/EP3325509B1/en active Active
- 2016-07-21 US US15/746,590 patent/US11230605B2/en active Active
-
2021
- 2021-03-09 CY CY20211100200T patent/CY1123941T1/el unknown
- 2021-12-09 US US17/546,208 patent/US12037408B2/en active Active